Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Chemotherapy. Immunotherapy. Istituto Oncologico Veneto, Padova, Italy

Survival: 8.7 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: Italy
City/State/Province: Padova
Hospital: Istituto Oncologico Veneto
Journal: Link
Date: 6/2011

This phase III study involved stage IV melanoma patients who were divided into two separate treatment groups. Group A consisted of 75 patients with a median age of 54.5 years and 61% male. Group B had 74 patients with a median age of 51.2 years and 61% male.

Patients in group A were treated with the chemotherapy agents cisplatin and dacarbazine, as well as the immunotherapy agent interleukin-2 (IL-2), which stimulates the immune system to fight cancer cells.
Patients in group B were treated with cisplatin, IL-2, and the chemotherapy agent temozolomide.

The most severe treatment toxicity in group A was of grade 4 and included neutropenia (5% of patients) and thrombocytopenia (4%). Grade 3 fatigue and nausea/vomiting were also reported.

For group B, the most severe toxicity was of grade 4, including neutropenia (9% of patients), thrombocytopenia (5%), and fatigue (3%). Grade 3 fever and nausea/vomiting were also reported.

The reported median overall survival for groups A and B was 8.7 and 8.4 months, respectively.

The temozolomide study drug was provided by Schering-Plough Corp.

Correspondence: Dr. V Chiarion-Sileni; email:

E-mail to a Friend Email Physician More Information